ÂÜÀòÂÒÂ×

Chris McChalicher is the Vice President of CMC Technology Development at Seres Therapeutics, where Chris leads Analytical, Bioprocessing, and Formulation Development activities. Prior to joining Seres Therapeutics, Chris held various roles at Metabolix, focusing on bench-scale evaluation of production strains and metabolic engineering. Chris also served as a 3M Science and Technology Fellow at the University of Minnesota, conducting research on PHA block copolymers. Chris holds a Bachelor's degree in Chemical Engineering from the University of Delaware and completed their graduate studies in Chemical Engineering at the University of Minnesota.